Tapotoclax (AMG 176) with Azacitidine Phase I trial in Subjects with Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

AMG 176 (Tapotoclax) is an orally bioavailable, highly potent and selective Mcl-1 inhibitor, binding reversibly to BH3- groove of the protein with a Ki value in picomolar range.

Demonstrate in vitro and in vivo antitumor efficacy in Mcl-1 dependent cancer models. It is currently in clinical evaluation for the treatment of hematologic malignancies.

On Nov 28th, 2022, Amgen  updated its P1 study of AMG-176 (MCL-1 inhibitor) + AZA in 1L HR-MDS and HMA-refractory MDS:

Study status: to “Recruiting” (from “Not yet recruiting”)

• 1 US-based trial site was added
• The enrollment number remains as 120 participants

source